Form 4: Artivion SVP Marshall S. Stanton Reports Stock Transactions
SEC Form 4 Filing
Artivion's SVP, Clinical & MD Affairs, Marshall S. Stanton, reports acquisition and disposal of common stock related to performance stock units.
Summary
- Marshall S. Stanton, SVP at Artivion, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On February 23, 2024, Stanton acquired 5,386 shares of common stock related to performance stock units granted on February 22, 2023.
- Also on February 23, 2024, Stanton acquired 10,644 shares of common stock related to performance stock units granted on February 22, 2023.
- On February 26, 2024, Stanton sold 1,600 shares at $20.2711 per share to cover tax withholding obligations.
- On February 26, 2024, Stanton sold 1,448 shares at $20.2711 per share to cover tax withholding obligations.
- Following these transactions, Stanton beneficially owns 81,685 shares of Artivion common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing primarily reflects routine stock transactions related to compensation and tax obligations.
Positives
- The vesting of performance stock units indicates that performance targets were met, which is a positive signal.
Future Outlook
Remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the healthcare industry.
Comparison to Industry Standards
- Similar insider transactions are regularly reported by executives at comparable medical device companies such as Medtronic, Boston Scientific, and Abbott Laboratories.
- These transactions are typically related to stock option exercises, vesting of restricted stock units, or sales to cover tax obligations.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/22/2023 | Date of grant for performance stock units |
| 02/23/2024 | Date of acquisition of 5,386 and 10,644 shares |
| 02/26/2024 | Date of sale of 1,600 and 1,448 shares |
| 02/22/2025 | 25% of remaining shares from Feb 2023 grant eligible to vest |
| 02/22/2026 | 25% of remaining shares from Feb 2023 grant eligible to vest |
| 02/28/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.